Novomedopa en es it fr

Novomedopa Brand names, Novomedopa Analogs

Novomedopa Brand Names Mixture

  • No information avaliable

Novomedopa Chemical_Formula


Novomedopa RX_link

Novomedopa fda sheet

Novomedopa FDA

Novomedopa msds (material safety sheet)

Novomedopa MSDS

Novomedopa Synthesis Reference

No information avaliable

Novomedopa Molecular Weight

1270.28 g/mol

Novomedopa Melting Point

No information avaliable

Novomedopa H2O Solubility

Freely soluble as sodium salt (> 200mg/mL)

Novomedopa State


Novomedopa LogP

No information avaliable

Novomedopa Dosage Forms

Powder for solution (for injection)

Novomedopa Indication

For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Novomedopa Pharmacology

Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.

Novomedopa Absorption

No information avaliable

Novomedopa side effects and Toxicity

Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.

Novomedopa Patient Information

No information avaliable

Novomedopa Organisms Affected

Aspergillis, Candida and other fungi